

1 **Anti-cardiolipin and other anti-phospholipid antibodies in critically ill COVID-19 positive and**
2 **negative patients**

3

4 Uriel Trahtemberg MD, PhD¹; Robert Rottapel MD^{2,3}; Claudia C dos Santos MD^{1,4,5}; Arthur S.
5 Slutsky, MD^{4,5}; Andrew J Baker MD^{1,4,5}; Marvin J Fritzler MD, PhD*⁶ on behalf of the COVID19
6 Longitudinal Biomarkers of Lung Injury (COLOBILI) group.

7

8 1. Critical Care Department, St. Michael's Hospital, Toronto, ON, Canada.

9 2. Departments of Medicine and Immunology, University of Toronto, Toronto, ON, Canada.

10 3. Division of Rheumatology, St. Michael's Hospital, Toronto, ON, Canada.

11 4. Keenan Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael's
12 Hospital, Toronto, ON, Canada.

13 5. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON,
14 Canada

15 6. Cumming School of Medicine, University of Calgary, Calgary, AB Canada.

16

17 * Corresponding author:

18 Marvin J. Fritzler PhD MD

19 Cumming School of Medicine

20 University of Calgary

21 3330 Hospital Dr. NW

22 Calgary, AB, Canada T2N 4N1

23 Email: fritzler@ucalgary.ca

24 Telephone: +01-403-220-3533

25 ORCID ID: [0000-0003-1652-6608](https://orcid.org/0000-0003-1652-6608)

26

27 Abstract word count: 197

28 Manuscript word count: 1493

29 References: 20

30 Figures & Tables: 3

31 Supplemental Tables: 3

32

33 **ABSTRACT**

34 **Background:** Reports of severe COVID-19 being associated with thrombosis, anti-phospholipid
35 antibodies (APLA), anti-phospholipid syndrome (APS) have yielded disparate conclusions.
36 Studies comparing COVID-19 patients with contemporaneous controls of similar severity are
37 lacking.

38 **Methods:** 22 COVID⁺ and 20 COVID⁻ patients with respiratory failure admitted to intensive care
39 were studied longitudinally. Demographic and clinical data were obtained from the day of
40 admission. APLA testing included anti-cardiolipin (aCL), anti-β₂glycoprotein 1 (β₂GP1), anti-
41 domain 1 beta2 glycoprotein 1 (β₂GP1) and anti-phosphatidyl serine/prothrombin complex
42 (PS/PT). Anti-nuclear antibodies (ANA) were detected by immunofluorescence and antibodies to
43 cytokines by a commercially available multiplexed array. ANOVA was used for continuous
44 variables and Fisher's exact test was used for categorical variables with $\alpha=0.05$ and the false
45 discovery rate at $q=0.05$.

46 **Results:** APLA were predominantly IgG aCL (48%) followed by IgM (21%) in all patients, with a
47 tendency toward higher frequency among the COVID⁺. aCL was not associated with surrogate
48 markers of thrombosis but IgG aCL was strongly associated with worse disease severity and
49 higher ANA titers regardless of COVID-19 status. An association between aCL and anti-cytokine
50 autoantibodies tended to be higher among the COVID⁺.

51 **Conclusions:** Positive APLA serology was associated with more severe disease regardless of
52 COVID-19 status.

53

54 **KEYWORDS:** Antiphospholipid; anticardiolipin; COVID-19; critical care; lung injury.

55

56

57 INTRODUCTION

58 Anti-phospholipid antibodies (APLA) are biomarkers of a spectrum of clinical features observed
59 in anti-phospholipid syndrome (APS) ¹. Features of APS include venous and arterial thrombosis
60 involving multiple organs and having various presentations ¹. APLA that are components of APS
61 criteria include IgG and/or IgM anti-cardiolipin (aCL), - β 2-glycoprotein1 (GP1), and the “lupus
62 anticoagulant” (LAC)². Other non-criteria APLA such as anti-phosphatidylserine/prothrombin
63 (PS/PT) complex, -PT, and -domain 1 of β 2-GP1 have also found a diagnostic niche in APS^{3,4}.

64

65 One of the salient features of COVID-19 is the development of thrombotic events associated
66 with severe morbidity and mortality ⁵⁻⁸. In the context of systemic inflammation and
67 dysregulated immunity⁹, some reports have linked APLA to these thromboses ^{10,11}, severe
68 COVID-19^{5,12} and release of neutrophil extracellular traps⁵. However, APLA are also described in
69 a variety of other infectious diseases¹³ and critically ill patients have high rates of
70 thromboembolism that were not linked to APS or APLA¹⁴. Therefore, the association of COVID-
71 19 with APLA and their potential pathogenic role ¹⁵ has not been clearly demonstrated due to
72 the lack of contemporaneous, COVID-19 negative controls. Here we compare the prevalence
73 and clinical correlations of APLA in patients with severe COVID-19 as compared to
74 contemporaneous non-COVID19 patients with similar clinical characteristics.

75

76 METHODS

77 This is an observational cohort study of patients admitted to St. Michael’s Hospital (Toronto,
78 ON, Canada), as approved by the Research Ethics Board (REB# 20-078). Informed consent was
79 obtained from all patients or their legal surrogates. Inclusion criteria were age \geq 18 years,
80 admission to intensive care unit (ICU) with acute respiratory failure. Exclusion criteria were
81 inability to ascertain the primary outcome or obtain a baseline blood sample, and SARS-CoV2
82 infection in the 4 weeks prior to admission. COVID-19 status was determined with PCR of
83 nasopharyngeal swabs and/or endotracheal aspirates. Follow-up was 3 months post-ICU
84 admission or hospital discharge. Primary outcome was death in the ICU. Secondary outcomes
85 were in hospital-death, ICU utilization metrics, organ dysfunction measures and severity scores.
86 Clinical data and serum samples were collected longitudinally at days 0, 1, 3, 5, 7 and 10; after
87 day 10 or ICU discharge. Anti-CL, anti- β 2-GP1 and anti-PS/PT were tested for IgG and IgM, as
88 well as IgG anti-domain 1 β 2-GP1; all by ELISA or chemiluminescence (Inova Diagnostics, San

89 Diego, CA USA). ANOVA was used for continuous variables and Fisher's exact test was used for
90 categorical variables at $\alpha=0.05$, followed by a false discovery rate adjustment at $q=0.05$. Detailed
91 methods are available (online supplement), including methods for detection of anti-nuclear
92 autoantibodies (ANA) by HEp-2 immunofluorescence assay (IFA) (Inova Diagnostics, San Diego,
93 CA USA), and antigen-specific autoantibodies (TheraDiag, Paris, France) and anti-cytokine
94 autoantibodies (Millipore, Oakville, ON, Canada) using addressable laser bead immunoassays.
95

96 **RESULTS**

97 The demographic and clinical parameters of 22 COVID-19 positive (COVID⁺) and 20 COVID-19
98 negative (COVID⁻) patients (Table 1) included an average of 14.1 day stays in ICU and 31%
99 mortality, but no statistically significant differences between the two cohorts, including the lack
100 of significant differences in the number of thrombotic events requiring therapeutic
101 anticoagulation, platelet counts, or platelet counts normalized to the neutrophil counts (to index
102 for severity) (Table 1). None of the patients had a history of antecedent APS, systemic lupus
103 erythematosus (SLE) or other conditions associated with APS, nor were there significant
104 differences in other past medical history between COVID⁺ and COVID⁻ patients (supplemental
105 table 1).

106

107 **Frequency, development and distribution of aCL.** Forty-eight percent of all the ICU cohort had a
108 positive IgG aCL test (Table 1); interestingly, fewer patients had elevated titers of IgM aCL (n=9,
109 21%), with only 2 patients having IgM without IgG. Although more COVID⁺ had aCL antibodies,
110 the difference was not statistically significant. Longitudinally testing for anti- β 2-GP1 and anti-
111 PS/PT for IgG and IgM, as well as domain 1 β 2-GP1 IgG revealed only one patient (COVID⁺) with
112 positive serology for any of these autoantibodies. This patient seroconverted to IgM anti-PS/PT
113 at days 5-7 of ICU hospitalization. Table 2 shows the temporal development of the aCL IgG and
114 IgM antibodies stratified by COVID status. Late appearing (beyond 10 days after admission) aCL
115 antibodies were not included in the statistical analyses to avoid survival and availability bias.
116 Anti-CL were not associated with age or sex (not shown).

117

118 **aCL vs disease severity, platelet counts and need for anticoagulation.** Patients positive for aCL
119 IgG demonstrated a consistent trend for worse outcomes in all the measures tested but this did

120 not reach statistical significance after adjusting for multiple comparisons (Table 3). These trends
121 remained when analyzed separately for COVID⁺ and COVID⁻ (not shown). Anti-CL IgG positive
122 patients showed no significant differences in platelet counts, platelet to neutrophil ratio or the
123 need for therapeutic anticoagulation (Table 3).

124

125 **aCL association with ANA, antigen-specific autoantibodies and anti-cytokine autoantibodies.**

126 Although aCL IgG positivity was not associated with the presence of HEp-2 IFA ANA at a dilution
127 of 1:160, it was significantly associated with higher ANA titers ($p=0.02$), and this trend remained
128 when analyzing the COVID⁺ and COVID⁻ patients separately. IgG aCL positivity was also
129 significantly associated with anti-cytokine autoantibodies, both when analyzed for positive or
130 high-positive anti-cytokine titers ($p=0.003$ for both, adjusted for multiple comparisons); this was
131 not related to any particular anti-cytokine autoantibody, although anti-interferon- γ , anti-IL10
132 and anti-IL-17f were the most prevalent (supplemental table 2). When analyzing the aCL IgG
133 positive according to their COVID-19 status, the COVID⁺ had significantly higher levels of anti-
134 cytokine autoantibodies than the COVID⁻ (supplemental Table 3). Anti-CL IgG was not associated
135 with antigen-specific autoantibodies, including SLE and myositis-related autoantibodies (not
136 shown).

137

138 **DISCUSSION**

139 The key observation of this study is that patients with positive IgG aCL showed a trend toward
140 more severe disease regardless of whether they were COVID⁺ and COVID⁻. That is, while COVID⁺
141 patients showed non-significant trends towards worse respiratory outcomes when compared to
142 COVID⁻, aCL status had an independent association with disease severity, and did not modulate
143 the outcomes differentially based on COVID status. The pathological significance of aCL
144 seropositivity is unclear since there were no major differences in platelet counts or thrombotic
145 events in the two cohorts. Others have reported a high prevalence of aCL autoantibodies among
146 COVID⁺ patients, but these studies lacked contemporaneous COVID⁻ control groups of similar
147 disease severity^{5 6 16 17}.

148

149 Although aCL tended to associate with COVID⁺, they did not associate with the presence of other
150 antigen-specific autoantibodies, although they had a strong association with certain anti-
151 cytokine autoantibodies. Interestingly, some patients had positive IgG aCL serology on ICU

152 admission (Table 2) in the absence of another relevant comorbidity such as APS or SLE
153 (supplementary table 1). These observations suggest that aCL positivity in the setting of acute
154 severe respiratory illness may be a marker of a unique phenotype with variable temporal
155 expression of aCL and anti-cytokine antibodies. The temporal dynamic is evidenced by the
156 relatively long timeframe from symptom onset to ICU admission to the development of IgG aCL
157 (Table 3). Our findings highlight the importance of longitudinal monitoring of acutely ill patients.
158 It seems plausible that disparate conclusions in the literature with respect to the significance of
159 APLAs in COVID-19 may relate to arbitrary sampling times and lack of longitudinal follow up in
160 the setting of dynamic inflammatory diseases.

161

162 While some reports have included lupus anticoagulant (LAC) in their analyses, we did not
163 because LAC is known to be an unreliable biomarker in severe illnesses where, C-reactive
164 protein, anti-coagulant use and other factors confound its detection^{18,19}. In this study, we used
165 the anti-PS/PT test regarded by some as a surrogate for LAC (reviewed in³). However, only one
166 patient developed anti-PS/PT 5-7 days after admission. Further, our observation that no patient
167 had antibodies to β 2-GP1 (an APS criteria antibody) or to domain 1 β 2-GPI (reportedly higher
168 specificity for APS) argues against the presence of APS in our cohort. In a study of 37 COVID+
169 acute respiratory disease versus 31 pre-pandemic (not contemporaneous) acute respiratory
170 disease controls using a sample collected within 48 hours of admission, Frapard, et al. reported
171 that 37 COVID patients exhibited more thrombotic events as compared to 31 pre-pandemic
172 controls but the occurrence of APLA in the two groups was similar²⁰. Using APLA assays similar
173 to ours, Borghi, *et al.* reported a low prevalence of APLA in COVID+ sera, where the most
174 common target was IgG β 2-GP1 (15.6%)¹⁷. In addition, the primary β 2GP1 antibody targets were
175 in domains 2-4 which are less specific for APS¹⁷. In agreement with our study, Bertin *et al.*¹² and
176 Borghi *et al.*¹⁷ concluded that APLA were not associated with major thrombotic events.

177

178 The main limitation of our study is the small sample size. The strengths of our study include its
179 prospective, contemporaneous COVID- cohort with similar severity of disease. Importantly, we
180 tested a broad APLA serological panel longitudinally, providing a more robust assessment of its
181 true prevalence and incidence than in other reported studies; this is particularly relevant for
182 such acutely ill patients with dynamic clinical courses. Finally, our use of an extensive serological
183 panel allowed us to better characterize the broad phenotype associated with aCL.

184 **KEY MESSAGES**

185 **What is already known about this subject?**

- 186
- COVID-19 is associated with coagulopathy and high morbidity and mortality.
- 187
- COVID-19 shares some of these clinical features with anti-phospholipid syndrome.
- 188
- Reports of an association of anti-phospholipid antibodies with high risk COVID-19 have
- 189 yielded disparate conclusions, but they lacked longitudinal follow up and control groups
- 190 of similar severity.

191

192 **What does this study add?**

- 193
- Anti-phospholipid syndrome serology assessed longitudinally was predominantly
- 194 anticardiolipin IgG autoantibodies, in 48% of patients.
- 195
- Anticardiolipin serology was associated with worse disease severity in both COVID-19
- 196 positive and negative patients.

197

198 **How might this impact on clinical practice or future developments?**

- 199
- The use of anti-phospholipid antibodies tests in the COVID-19 clinical setting needs to
- 200 be taken in context; whereas they are associated with more severe disease, they do not
- 201 discriminate between COVID-19 positive and negative patients.

202 **DECLARATIONS**

203 **Ethics approval and consent to participate**

- 204 • This research was approved by Research Ethics Boards at St Michael's Hospital and
205 performed in accordance with the Helsinki Declaration of 1975 as revised in 2013.

206 **Consent for publication**

- 207 • Not applicable

208 **Availability of data and materials**

- 209 • The datasets used and/or analysed during the current study are available from the
210 corresponding author on reasonable request.

211 **Competing interests**

- 212 • MJF is the Director of MitogenDx. MJF is a consultant for and received speaking honoraria
213 from Inova Diagnostics Inc (San Diego, CA) and Werfen International (Barcelona, Spain). All
214 the other authors have no disclosures to declare.

215 **Funding**

- 216 • St Michael's Hospital Foundation, internal competitive grant to AB and CDS.
217 • Autoantibody testing was provided as a gift in kind by MitogenDx (Calgary, AB, Canada)

218 **Authors' contributions**

- 219 • This report is part of the COLOBILI study (Coronavirus longitudinal biomarkers in lung injury).
220 AB and CDS are principal investigators; MJF, RR and AS are collaborators/co-investigators
221 and UT is the research lead.
222 • RR, MJF, UT, and CDS conceived of the study; MJF, UT and RR wrote the manuscript drafts;
223 AS, AB and CDS provided critique and technical guidance; UT performed the data analysis
224 and creation of the figures. All authors edited the manuscript, through to the final version,
225 read and approved the final submission.

226 **Acknowledgements**

- 227 • The authors acknowledge the technical assistance of Haiyan Hou, Meifeng Zhang and Emily
228 Walker in the MitogenDx Laboratory at the University of Calgary. We thank Marlene Santos,
229 Gyan Sadhu, Imrana Khalid, and Sebastian Duncan, the research coordinators at St Michael's
230 Hospital Critical Care Research Unit. We are grateful to patients and families that have
231 generously consented to the study.

232 **Study registration**

- 233 • NCT04747782 – clinicaltrials.gov

234 **Patient and Public Involvement**

- 235 • Patients and public were not involved in the design of the study. During the initial phases of
236 the study, we obtained feedback from the patients and their substitute decision makers.
237 Their concerns, questions and preferences were incorporated into improved processes for
238 consent and collection of biological samples. The consent forms have checkboxes with
239 optional aspects of the study, to accommodate different patient preferences. The results of
240 the study will be disseminated in lay versions by St. Michael's Hospital public relations and
241 communications departments for the benefit of the public.

242

243

244

References

245

- 246 1 Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG et al. Characteristics of
247 Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for
248 Clinical Trials and InternatiOnal Networking. *Arthritis Care Res (Hoboken)* 2020; Online
249 ahead of print:-doi: 10.1002/acr.24468.
- 250 2 Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo MC, Avcin T, Bertolaccini ML et al.
251 Development of New International Antiphospholipid Syndrome Classification Criteria
252 Phase I/II Report: Generation and Reduction of Candidate Criteria. *Arthritis Care Res*
253 *(Hoboken)* 2020; Online ahead of print:-doi: 10.1002/acr.24520.
- 254 3 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-
255 prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the
256 risk of thrombosis in the antiphospholipid syndrome. A systematic review. *Thromb*
257 *Haemost* 2014; 111:354-364.
- 258 4 Noordermeer T, Molhoek JE, Schutgens REG, Sebastian SAE, Drost-Verhoef S, van Wesel
259 ACW et al. Anti- β 2-glycoprotein I and anti-prothrombin antibodies cause lupus
260 anticoagulant through different mechanisms of action. *J Thromb Haemost* 2021.
- 261 5 Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H et al. Prothrombotic autoantibodies
262 in serum from patients hospitalized with COVID-19. *Sci Transl Med* 2020; 12(570):3876-
263 doi: 10.1126/scitranslmed.abd3876.
- 264 6 El HG, Taher AT, Jawad A, Uthman I. COVID-19, Antiphospholipid Antibodies, and
265 Catastrophic Antiphospholipid Syndrome: A Possible Association? *Clin Med Insights*
266 *Arthritis Musculoskelet Disord* 2020; 13:1-8. doi: 10.1177/1179544120978667.
- 267 7 Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K.
268 Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence
269 and call for action. *Br J Haematol* 2020; 189:846-847.
- 270 8 Fan BE, Ng J, Chan SSW, Christopher D, Tso ACY, Ling LM et al. COVID-19 associated
271 coagulopathy in critically ill patients: A hypercoagulable state demonstrated by
272 parameters of haemostasis and clot waveform analysis. *J Thromb Thrombolysis* 2020; On
273 line ahead of print. Oct 24:10-02318.
- 274 9 Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H et al. Coronavirus
275 Disease 2019 (COVID-19): An Overview of the Immunopathology, Serological Diagnosis
276 and Management. *Scand J Immunol* 2020;e12998.
- 277 10 Pineton de Chambrun M, Frere C, Miyara M, Amoura Z, Martin-Toutain I, Mathian A et al.
278 High Frequency of Antiphospholipid Antibodies in Critically-ill COVID-19 Patients: a Link
279 with Hypercoagulability? *J Intern Med* 2020; Online ahead of print. Jun 12.-doi:
280 10.1111/joim.13126.

- 281 11 Showers CR, Nuovo GJ, Lakhanpal A, Siegel CH, Aizer J, Elreda L et al. A Covid-19 Patient
282 with Complement-Mediated Coagulopathy and Severe Thrombosis. *Pathobiology* 2020;
283 2:1-9. doi: 10.1159/000512503.
- 284 12 Bertin D, Brodovitch A, Beziane A, Hug S, Bouamri A, Mege JL et al. Anti-cardiolipin IgG
285 autoantibodies are an independent risk factor of COVID-19 severity. *Arthritis Rheumatol*
286 2020; 72(11):1953-1955. doi: 10.1002/art.41409.
- 287 13 Mendoza-Pinto C, Garcia-Carrasco M, Cervera R. Role of Infectious Diseases in the
288 Antiphospholipid Syndrome (Including Its Catastrophic Variant). *Curr Rheumatol Rep* 2018;
289 20:62-0773.
- 290 14 Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid
291 antibodies. *J Thromb Haemost* 2020; 10.1111:jth.14893.-doi: 10.1111/jth.14893.
- 292 15 Radic M, Pattanaik D. Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome.
293 *Front Immunol* 2018; 9:969.
- 294 16 Tang N. Response to "Lupus anticoagulant is frequent in patients with Covid-19". *J Thromb*
295 *Haemost* 2020;10.
- 296 17 Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C et al. Anti-Phospholipid
297 Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid
298 Syndrome. *Front Immunol* 2020; 11:584241-doi: 10.3389/fimmu.2020.584241.
- 299 18 Gooding R, Myers B, Salta S. Lupus Anticoagulant in Patients with Covid-19. *N Engl J Med*
300 2020; 383:1893-doi: 10.1056/NEJMc2027508.
- 301 19 Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD. A Reality Check on Antiphospholipid
302 Antibodies in COVID-19-Associated Coagulopathy. *Arthritis Rheumatol* 2020; Online ahead
303 of print:-doi: 10.1002/art.41472.
- 304 20 Frapard T, Hue S, Rial C, de PN, Mekontso DA. Antiphospholipid antibodies and thrombosis
305 in patients with COVID-19. *Arthritis Rheumatol* 2020; Online ahead of print. Dec 31.-doi:
306 10.1002/art.41634.
307
308
309

310 **Table 1: Patient Demographic, Clinical and Autoantibody Status**

	Cohort	All	COVID⁺	COVID⁻
	N	42	22	20
Age	<i>Mean (CI)</i>	58.2 (62.7-54.1)	60.9 (66.6-55.3)	55.7 (62-48.7)
Sex	<i>% male</i>	29/42 (69%)	17/22 (77%)	12/20 (60%)
Censored?	<i>N (%)</i>	5/42 (12%)	4/22 (18%)	1/20 (5%)
Number of days before censoring	<i>Mean (CI)</i>	39.4 (59.4-19.4)	44.3 (66.2-22.3)	20 (NA)
Days from symptom onset to ICU	<i>Mean (CI)</i>	6 (8.3-3.7)	7.5 (9.9-5.2)	4.2 (8.5-0)
APACHE II on ICU admission	<i>Mean (CI)</i>	25.3 (27.6-22.9)	23.7 (27-20.4)	27 (30.5-23.5)
Mean of SOFA score for 1st 3 days	<i>Mean (CI)</i>	9.6 (10.7-8.5)	9.3 (11-7.7)	9.9 (11.6-8.3)
Mean of SOFA score for 1st 7 days	<i>Mean (CI)</i>	8.9 (10.1-7.8)	9.1 (11-7.3)	8.7 (10.3-7.2)
ICU days (censored)	<i>Mean (CI)</i>	14.1 (17.3-10.8)	14.2 (20.5-7.8)	14 (16.9-11.1)
Death in ICU	<i>N (%)</i>	13/42 (31%)	7/22 (32%)	6/20 (30%)
Mechanical ventilation days (censored)	<i>Mean (CI)</i>	14.4 (18.9-10)	16.8 (25.1-8.6)	11.8 (14.9-8.7)
Total days of ventilation rescue measures	<i>Mean (CI)</i>	2.9 (4.3-1.4)	4.4 (7-1.8)	1.2 (2-0.4)
Therapeutic anticoagulation used	<i>N (%)</i>	8/42 (19%)	3/22 (14%)	5/20 (25%)
Mean platelet count	<i>Mean (CI)</i>	239 (269-209)	264 (313-214)	212 (245-179)
Mean platelet to neutrophil ratio	<i>Mean (CI)</i>	35.2 (42-28.4)	38.7 (48.4-29)	31.4 (41.6-21.2)
aCL IgG	<i>N (%)</i>	20/42 (48%)	13/22 (59%)	7/20 (35%)
aCL IgM	<i>N (%)</i>	9/42 (21%)	7/22 (32%)	2/20 (10%)
Anti-β2GPI IgG	<i>N (%)</i>	0	0	0
Anti-β2GPI IgM	<i>N (%)</i>	0	0	0
Anti-domain 1 β2GP1 IgG	<i>N (%)</i>	0	0	0
Anti-PS/PT IgG	<i>N (%)</i>	0	0	0
Anti-PS/PT IgM	<i>N (%)</i>	1/42 (2%)	1/22 (5%)	0

311

312 **Abbreviations:** aCL, anticardiolipin; APACHE, Acute Physiology and Chronic Health Evaluation

313 (score); β2GP1, beta 2 glycoprotein I; ICU, intensive care unit; PS/PT, phosphatidyl

314 serine/prothrombin complex; SOFA, sequential organ failure assessment (score).

315

316 **Legend:** The data was censored on May 31, 2020. Days from symptom onset were self-reported

317 by the patients or their representatives. The SOFA score was performed daily for all patients; the

318 average was calculated for the first 3 and 7 days in the ICU for each patient, and the mean of
319 those averages are reported. For patients that underwent tracheostomy, mechanical ventilation
320 days are counted until successfully weaned from ventilatory support for 24 hrs. Rescue
321 measures included use of paralytics, proning and inhaled NO (counted additively if more than
322 one intervention used in the same day). The clinical outcomes were measured for up to 3
323 months. All the serologies were tested longitudinally and are reported for the first 10 days from
324 admission to the ICU (for standardization among patients). There was no statistically significant
325 difference between COVID⁺ and COVID⁻ patients for all variables, using ANOVA for continuous
326 variables and Fisher's exact test for categorical variables at $\alpha=0.05$, followed by the false
327 discovery rate at $q=0.05$.

328

329 **Table 2: Development of aCL IgG and IgM over time**

Cohort		aCL detected on admission	aCL developed within 10 days	Late appearing aCL (after 10 days)
aCL IgG positive	COVID ⁺	4	9	2
	COVID ⁻	3	4	
aCL IgM positive	COVID ⁺	1	6	2
	COVID ⁻	1	1	1

330 **Abbreviations:** aCL, anti-cardiolipin antibodies.

331 **Legend:** late aCL was not included in the statistical analyses to avoid survival and availability
332 bias, and is shown here for qualitative assessment.

333

334

335 **Table 3: Association between aCL IgG and disease severity, platelet counts and need for**
336 **anticoagulation**

	Cohort	All	aCL IgG positive	aCL IgG negative
	N	42	20	22
Age	<i>Mean (CI)</i>	58.2 (62.7-54.1)	55.9 (62.9-49)	60.7 (66.4-55)
Sex	<i>% male</i>	29/42 (69%)	13/20 (65%)	16/22 (73%)
Days from symptom onset to ICU	<i>Mean (CI)</i>	6 (8.3-3.7)	8.7 (12.8-4.6)	3.4 (5.4-1.5)
APACHE II on ICU admission	<i>Mean (CI)</i>	25.3 (27.6-22.9)	25.7 (28.5-22.9)	24.9 (28.8-20.9)
Mean of SOFA score for 1st 3 days	<i>Mean (CI)</i>	9.6 (10.7-8.5)	10.6 (12.2-9.1)	8.7 (10.3-7)
Mean of SOFA score for 1st 7 days	<i>Mean (CI)</i>	8.9 (10.1-7.8)	10 (11.7-8.4)	8 (9.5-6.4)
ICU days (censored)	<i>Mean (CI)</i>	14.1 (17.3-10.8)	16.6 (21.9-11.3)	12.1 (16.5-7.6)
Death in ICU	<i>N (%)</i>	13/42 (31%)	8/20 (40%)	5/22 (23%)
Mechanical ventilation days (censored)	<i>Mean (CI)</i>	14.4 (18.9-10)	18.2 (25.5-10.8)	11.1 (16.4-5.7)
Total days of ventilation rescue measures	<i>Mean (CI)</i>	2.9 (4.3-1.4)	3.6 (5.6-1.5)	2.3 (4.4-0.1)
Therapeutic anticoagulation used	<i>N (%)</i>	8	4/20 (20%)	4/22 (18%)
Mean platelet count	<i>Mean (CI)</i>	239 (269-209)	268 (321-216)	212 (246-179)
Mean platelet to neutrophil ratio	<i>Mean (CI)</i>	35.2 (42-28.4)	34.8 (45.2-24.3)	35.6 (45.4-28.9)

337

338 Abbreviations: aCL, anticardiolipin; APACHE, Acute Physiology and Chronic Health Evaluation
339 (score); ICU, intensive care unit; SOFA, sequential organ failure assessment (score).

340

341 Legend: See Table 1 for details on the variables shown. There were no statistically significant
342 differences between aCL IgG positive and aCL IgG negative patients for all variables, using
343 ANOVA for continuous variables and Fisher's exact test for categorical variables at $\alpha=0.05$,
344 followed by the false discovery rate at $q=0.05$.

345

346

347